• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Justin F. Gainor, MD

Publications

  • Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, Michellys PY, Awad MM, Yanagitani N, Kim S, Pferdekamper AC, Li J, Kasibhatla S, Sun F, Sun X, Hua S, McNamara P, Mahmood S, Lockerman EL, Fujita N, Nishio M, Harris JL, Shaw AT, Engelman JA.The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.Cancer Discovery. 2014 Jun(6):662-73.
    24675041
  • Gainor JF, Longo DL, Chabner BA.Pharmacodynamic biomarkers: falling short of the mark?.Clin Cancer Res. 2014 May 15;20(10):2587-94.
    24831281
  • Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT.The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer.J Thorac Oncol. 2013 Dec;8(12):1570-3.
    24389440
  • Gainor JF, Shaw AT.Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer.J Clin Oncol. 2013 Nov 1;31(31):3987-96.
    24101047
  • Gainor JF, Varghese AM, Ou SH, Kabraji S, Awad MM, Katayama R, Pawlak A, Mino-Kenudson M, Yeap BY, Riely GJ, Iafrate AJ, Arcila ME, Ladanyi M, Engelman JA, Dias-Santagata D, Shaw AT.ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.Clin Cancer Res. 2013 Aug 1;19(15):4273-81.
    23729361
  • Gainor JF, Shaw AT.Novel targets in non-small cell lung cancer: ROS1 and RET fusions.Oncologist. 2013;18(7):865-75.
    23814043
  • Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, Digumarthy SR, Stone JR, Mino-Kenudson M, Christensen JG, Iafrate AJ, Engelman JA, Shaw AT.Acquired resistance to crizotinib from a mutation in CD74-ROS1.N Engl J Med. 2013 Jun 20;368(25):2395-401.
    23724914
  • Gainor JF, Shaw AT.The new kid on the block: RET in lung cancer.Cancer Discovery. 2013 Jun;3(6):604-6.
    23749525